TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2615927

Group type: EXPERIMENTAL
Intervention: Clomipramine, 10 mg i.v.
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Desipramine, 25 mg i.m.
Number of subjects: 14
Study: 367865

Group type: EXPERIMENTAL
Intervention: metoprolol 100 mg
Number of subjects: 16
Study: 31394530

Group type: EXPERIMENTAL
Intervention: Emollient
Number of subjects: 459

Group type: EXPERIMENTAL
Intervention: Synbiotic
Number of subjects: 459

Group type: EXPERIMENTAL
Intervention: Both emollient and synbiotic
Number of subjects: 459

Group type: COMPARATOR
Intervention: Neither emollient nor synbiotic (Control)
Number of subjects: 459
Study: 28145158

Group type: EXPERIMENTAL
Intervention: Sitagliptin (100 mg/day)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Sitagliptin (acute dosing)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Sitagliptin (chronic dosing)
Number of subjects: 38
Study: 26583659

Group type: EXPERIMENTAL
Intervention: Single-port laparoscopic cholecystectomy (SPLC)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Conventional 4-port laparoscopic cholecystectomy (4PLC)
Number of subjects: 110
Study: 23076293

Group type: EXPERIMENTAL
Intervention: Daily minodronate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Weekly alendronate
Number of subjects: 0
Study: 21696807

Group type: EXPERIMENTAL
Intervention: Doxazosin gastrointestinal therapeutic system (doxazosin-GITS) 4 mg
Number of subjects: 200

Group type: COMPARATOR
Intervention: Tamsulosin 0.2 mg
Number of subjects: 200
Study: 19465881

Group type: EXPERIMENTAL
Intervention: Escitalopram 10 to 20 mg/day
Number of subjects: 312

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 312
Study: 16951888

Group type: EXPERIMENTAL
Intervention: 30 minutes of tobacco abstinence
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: 60 minutes of tobacco abstinence
Number of subjects: 201

Group type: COMPARATOR
Intervention: 0 minutes of tobacco abstinence
Number of subjects: 201
Study: 15301577

Group type: EXPERIMENTAL
Intervention: Risperidone 2mg once daily on days 15 and 16, and 4 mg once daily on days 17-28
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 22
Study: 10952418

Group type: EXPERIMENTAL
Intervention: Nonselective endothelin-1 inhibitors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Selective endothelin A receptor inhibitors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nonselective antagonism of endothelin receptors
Number of subjects: 0
Study: 9222947

Group type: EXPERIMENTAL
Intervention: Drug therapy
Number of subjects: 637

Group type: EXPERIMENTAL
Intervention: Low-energy-intake diet compliance
Number of subjects: 637

Group type: COMPARATOR
Intervention: Low-sodium diet compliance
Number of subjects: 637

Group type: COMPARATOR
Intervention: Physical exercise compliance
Number of subjects: 637
Study: 8376442

Group type: EXPERIMENTAL
Intervention: Hamilton‐Russell skin traction
Number of subjects: 252

Group type: COMPARATOR
Intervention: Nursed free in bed
Number of subjects: 252
Study: 3527645

Group type: EXPERIMENTAL
Intervention: Diltiazem (0.28 mg/kg bolus pre-operatively, continuous infusion of 0.0022 mg/kg/min for 48 hours, followed by oral 60 mg twice daily)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control (no diltiazem)
Number of subjects: 42
Study: 31290698

Group type: EXPERIMENTAL
Intervention: Contingency management (CM) intervention; participants could earn R150 ($24) in abstinence-contingent incentives at each assessment.
Number of subjects: 87

Group type: COMPARATOR
Intervention: Control group (information and monitoring); n = 47.
Number of subjects: 87
Study: 29660637

Group type: EXPERIMENTAL
Intervention: Oral ketamine
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study: 26938953

Group type: EXPERIMENTAL
Intervention: Intravitreal anti-VEGF injections
Number of subjects: 21
Study: 24924874

Group type: EXPERIMENTAL
Intervention: Increased awareness and acceptance of emotions and thoughts during treatment
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Impulsivity (poor inhibitory control)
Number of subjects: 144
Study: 22278145

Group type: COMPARATOR
Intervention: HCTZ 25 mg
Number of subjects: 18

Group type: COMPARATOR
Intervention: Cicletanine 50 mg
Number of subjects: 18

Group type: COMPARATOR
Intervention: Cicletanine 150 mg
Number of subjects: 18
Study: 20578209

Group type: EXPERIMENTAL
Intervention: sotrastaurin 100 mg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: cyclosporine 400 mg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 100 mg sotrastaurin with 400 mg cyclosporine
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 100 mg sotrastaurin with 100 mg cyclosporine
Number of subjects: 20
Study: 18667823

Group type: EXPERIMENTAL
Intervention: 5 microg ramosetron hydrochloride
Number of subjects: 418

Group type: EXPERIMENTAL
Intervention: 10 microg ramosetron hydrochloride
Number of subjects: 418

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 418
Study: 16208701

Group type: EXPERIMENTAL
Intervention: Docetaxel plus trastuzumab
Number of subjects: 169

Group type: COMPARATOR
Intervention: Paclitaxel plus trastuzumab
Number of subjects: 169
Study: 11978749

Group type: EXPERIMENTAL
Intervention: Iron supplementation during infancy
Number of subjects: 401

Group type: COMPARATOR
Intervention: Low birth weight (LBW)
Number of subjects: 401

Group type: COMPARATOR
Intervention: Fetal anaemia (FA)
Number of subjects: 401

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: Parity, placental and maternal malaria at delivery, and sex
Number of subjects: 401
Study: 10219864

Group type: EXPERIMENTAL
Intervention: Direct trocar insertion
Number of subjects: 1500

Group type: COMPARATOR
Intervention: Veress needle insertion
Number of subjects: 1500
Study: 7767427

Group type: EXPERIMENTAL
Intervention: Racemic epinephrine (REP group; n = 24)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Albuterol (AP group; n = 27)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Physiologic saline followed by racemic epinephrine (PRE group; n = 24)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Physiologic saline followed by albuterol (PA group; n = 25)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Intramuscular epinephrine
Number of subjects: 100

Group type: COMPARATOR
Intervention: Physiologic saline
Number of subjects: 100
Study: 2145384

Group type: EXPERIMENTAL
Intervention: Experimental group (spinal adjustive manipulation)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Sham group (light physical contact)
Number of subjects: 18
Study: 7028411

Group type: EXPERIMENTAL
Intervention: Cefuroxime 750 mg, intramuscular injection, three times daily for 7-10 days
Number of subjects: 111

Group type: COMPARATOR
Intervention: Ampicillin 500 mg, intramuscular injection, three times daily for 7-10 days
Number of subjects: 111
Study: 29496350

Group type: EXPERIMENTAL
Intervention: PCSDM curriculum plus fact-based immunization curriculum
Number of subjects: 143

Group type: COMPARATOR
Intervention: Fact-based immunization curriculum alone
Number of subjects: 143
Study: 26872475

Group type: EXPERIMENTAL
Intervention: Audio-recorded vignette presenting sexual assault threat
Number of subjects: 139
Study: 25216508

Group type: EXPERIMENTAL
Intervention: Spinal cord stimulation (SCS) in combination with best medical treatment (BMT)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Best medical treatment (BMT) only
Number of subjects: 36
Study: 23046029

Group type: EXPERIMENTAL
Intervention: Intense pulsed light (IPL) combined with bleaching agents and broad-spectrum sunscreens
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control group receiving only bleaching agents and broad-spectrum sunscreens
Number of subjects: 62
Study: 20120423

Group type: EXPERIMENTAL
Intervention: Dapsone gel 5% combined with adapalene gel 0.1%
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Dapsone gel 5% combined with benzoyl peroxide gel 4%
Number of subjects: 301

Group type: COMPARATOR
Intervention: Dapsone gel 5% combined with moisturizer
Number of subjects: 301
Study: 17849435

Group type: EXPERIMENTAL
Intervention: Home exercise programme (training once a day)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Control group (without exercise)
Number of subjects: 57
Study: 15857227

Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitoring System (CGMS) for patients with type 1 diabetes
Number of subjects: 20

Group type: COMPARATOR
Intervention: Continuous Glucose Monitoring System (CGMS) for healthy controls
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: CONGA (Continuous overall net glycemic action)
Number of subjects: 20
Study: 12385861

Group type: EXPERIMENTAL
Intervention: 17beta‐oestradiol/norethisterone acetate
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: tibolone
Number of subjects: 80
Study: 10592724

Group type: EXPERIMENTAL
Intervention: Very extensive metabolizers of sparteine (patients with allergic diseases)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Healthy volunteers (control group)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Patients with very extensive oxidation phenotype
Number of subjects: 200
Study: 8909483

Group type: EXPERIMENTAL
Intervention: PRP-meningococcal protein conjugate (M) at 2 months followed by PRP-tetanus toxoid conjugate (T) at 4 and 6 months
Number of subjects: 321

Group type: EXPERIMENTAL
Intervention: Two-dose mixed regimen (M at 2 months and T at 4 months)
Number of subjects: 321

Group type: COMPARATOR
Intervention: Three-dose TTT regimen
Number of subjects: 321

Group type: EXPERIMENTAL
Intervention: Two-dose mixed regimen (MT-)
Number of subjects: 321
Study: 1858696

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 6405772

Group type: EXPERIMENTAL
Intervention: Codeine 60 mg by mouth
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 31813423

Group type: EXPERIMENTAL
Intervention: Task-oriented training (TOT)
Number of subjects: 46
Study: 29806413

Group type: EXPERIMENTAL
Intervention: Photoelectric guided navigation unilateral puncture of the percutaneous kyphoplasty (PKP)
Number of subjects: 85

Group type: COMPARATOR
Intervention: C arm fluoroscopy unilateral puncture of the percutaneous kyphoplasty (PKP)
Number of subjects: 85
Study: 26845273

Group type: EXPERIMENTAL
Intervention: Antipsychotic polypharmacy (APP)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Antipsychotic monotherapy (APM)
Number of subjects: 35
Study: 24872442

Group type: EXPERIMENTAL
Intervention: Supervised exercise program (EP) consisting of three, 55‐ to 60‐min sessions per week throughout pregnancy
Number of subjects: 184

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 184
Study: 22820469

Group type: EXPERIMENTAL
Intervention: Unworn silicone hydrogel lenses
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Worn silicone hydrogel lenses
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Silicone hydrogel lenses (general)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: P. aeruginosa
Number of subjects: 10
Study: 20150814

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention at a community hospital without on-site surgical backup
Number of subjects: 609

Group type: COMPARATOR
Intervention: Percutaneous coronary intervention at a regional hospital with on-site surgical backup
Number of subjects: 609

Group type: EXPERIMENTAL
Intervention: Both hospitals (with and without surgical backup)
Number of subjects: 609
Study: 19033147

Group type: EXPERIMENTAL
Intervention: Web-assisted tobacco interventions (WATI)
Number of subjects: 0
Study: 16038681

Group type: EXPERIMENTAL
Intervention: PTSD subjects
Number of subjects: 14

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 14
Study: 12490031

Group type: EXPERIMENTAL
Intervention: TAMMEF (musically modulated electromagnetic field)
Number of subjects: 150

Group type: COMPARATOR
Intervention: ELF (100 Hz electromagnetic field)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Simulated treatment
Number of subjects: 150
Study: 10634161

Group type: EXPERIMENTAL
Intervention: Magnesium citrate (250 mL) and bisacodyl (10 mg, orally)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Castor oil (60 mL, orally)
Number of subjects: 70
Study: 7572119

Group type: EXPERIMENTAL
Intervention: Post-operative radiotherapy (RT)
Number of subjects: 1358

Group type: COMPARATOR
Intervention: Pre-operative radiotherapy (RT)
Number of subjects: 1358
Study: 1959859

Group type: EXPERIMENTAL
Intervention: Parenteral amino acid administration (2 l/day of a solution of dextrose (65 gm/L) and amino acids (25.8 gm/L) for 1 month)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Parenteral amino acid administration
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control (dextrose solution only)
Number of subjects: 54
Study: 6394008

Group type: EXPERIMENTAL
Intervention: Nutritional supplementation
Number of subjects: 682

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 682
Study: 31610948

Group type: EXPERIMENTAL
Intervention: Mini-open antegrade intramedullary nailing (AIN)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Low-profile locking plate
Number of subjects: 75
Study: 27258736

Group type: EXPERIMENTAL
Intervention: Psoralen plus ultraviolet A (PUVA) for 90 days
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Narrowband ultraviolet B (NB-UVB) for 90 days
Number of subjects: 50
Study: 27572830

Group type: EXPERIMENTAL
Intervention: TAK-063 (1000 mg)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: TAK-063 (100 mg) under fed conditions
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: TAK-063 (various doses)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: CNS Vital Signs cognitive assessment
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study: 24399265

Group type: EXPERIMENTAL
Intervention: Meat-based complementary feeding
Number of subjects: 1236

Group type: COMPARATOR
Intervention: Fortified cereal complementary feeding
Number of subjects: 1236

Group type: EXPERIMENTAL
Intervention: Study messages (general intervention)
Number of subjects: 1236
Study: 21909815

Group type: EXPERIMENTAL
Intervention: batroxobin (group B)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: tranexamic acid (TXA) (group C)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: combination of batroxobin and TXA (group D)
Number of subjects: 80

Group type: COMPARATOR
Intervention: 0.9% saline (group A)
Number of subjects: 80
Study: 19132338

Group type: EXPERIMENTAL
Intervention: Vasopressin (0.0005 U/kg/min)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Sodium chloride (0.9%)
Number of subjects: 24
Study: 17663820

Group type: EXPERIMENTAL
Intervention: Insulin enteric-coated soft capsules (50 IU)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Regular insulin (15 IU)
Number of subjects: 20
Study: 17602979

Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 3029
Study: 15641629

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate/salmeterol HFA 134A MDI (FSC)
Number of subjects: 360

Group type: COMPARATOR
Intervention: Placebo HFA 134a (PLA)
Number of subjects: 360

Group type: COMPARATOR
Intervention: Fluticasone propionate 44 microg CFC (FP)
Number of subjects: 360

Group type: COMPARATOR
Intervention: Salmeterol 21 microg CFC (S)
Number of subjects: 360
Study: 10678408

Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: HRT
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 23
Study: 9352280

Group type: EXPERIMENTAL
Intervention: Color Doppler imaging (CDI) in patients with mild to moderate vasculitis
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Color Doppler imaging (CDI) in patients with severe vasculitis
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (healthy volunteers)
Number of subjects: 50
Study: 8211801

Group type: EXPERIMENTAL
Intervention: Theopek taken twice daily
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Euphylong taken in a single daily dose
Number of subjects: 59
Study: 3082230

Group type: EXPERIMENTAL
Intervention: metrifonate (10 mg/kg body weight, twice)
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: oxamniquine (60 mg/kg)
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: praziquantel (40 mg/kg)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 156
Study: 31835620

Group type: COMPARATOR
Intervention: Zanthoxylum armatum (ZA) extract (single dose on Day 1)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Zanthoxylum armatum (ZA) extract (56 days supplementation)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Zanthoxylum armatum (ZA) extract (Day 1 and Day 56)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study: 28424902

Group type: EXPERIMENTAL
Intervention: AYA
Number of subjects: 205

Group type: COMPARATOR
Intervention: non-AYA
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: AYA and non-AYA
Number of subjects: 205
Study: 25944520

Group type: EXPERIMENTAL
Intervention: Pittsburgh Sleep Quality Index (PSQI)
Number of subjects: 849
Study: 24473958

Group type: COMPARATOR
Intervention: Continuous infusion group (CIG)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Intermittent infusion group (IIG)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 140
Study: 21879896

Group type: EXPERIMENTAL
Intervention: Early analysis of cardiac rhythm (30 to 60 seconds of CPR before analysis)
Number of subjects: 9933

Group type: COMPARATOR
Intervention: Later analysis of cardiac rhythm (180 seconds of CPR before analysis)
Number of subjects: 9933
Study: 19700284

Group type: EXPERIMENTAL
Intervention: EasyTube (EzT)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Endotracheal tube (ETT)
Number of subjects: 200
Study: 16525751

Group type: EXPERIMENTAL
Intervention: Yogurt (375 g/d)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Semi-skimmed milk (400 ml/d)
Number of subjects: 32
Study: 14722539

Group type: EXPERIMENTAL
Intervention: Argon plasma coagulation
Number of subjects: 40

Group type: COMPARATOR
Intervention: Endoscopic surveillance
Number of subjects: 40
Study: 11216725

Group type: EXPERIMENTAL
Intervention: Circular defect
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Rectangular defect
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Triangular defect
Number of subjects: 12

Group type: COMPARATOR
Intervention: Comparison between defect shapes
Number of subjects: 12

Group type: COMPARATOR
Intervention: Mode of failure
Number of subjects: 12
Study: 9684746

Group type: EXPERIMENTAL
Intervention: Ubiquinone supplementation (180 mg daily)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Lovastatin therapy
Number of subjects: 19
Study: 7798851

Group type: EXPERIMENTAL
Intervention: Intradermal regimen (0.1 ml at two sites on days 0, 3, 7 and 0.1 ml at one site on days 30 and 90)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard intramuscular regimen
Number of subjects: 100
Study: 3391735

Group type: EXPERIMENTAL
Intervention: Gastric bypass
Number of subjects: 51

Group type: COMPARATOR
Intervention: Gastroplasty
Number of subjects: 51
Study: 31421838

Group type: EXPERIMENTAL
Intervention: Mechanochemical ablation (MOCA)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Thermal ablation (radiofrequency ablation and endovenous laser therapy)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Thermal ablation
Number of subjects: 66
Study: 28117241

Group type: EXPERIMENTAL
Intervention: Patient specific rehearsal (PsR) prior to EVAR
Number of subjects: 100

Group type: COMPARATOR
Intervention: Post-operative PsR
Number of subjects: 100
Study: 26342026

Group type: EXPERIMENTAL
Intervention: High methylation index of AGTR1, FOXI2, and PENK promoters
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Low levels of LINE1 methylation
Number of subjects: 68
Study: 23845305

Group type: EXPERIMENTAL
Intervention: Praziquantel 25 mg/kg
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Praziquantel 50 mg/kg
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control group (no praziquantel)
Number of subjects: 53
Study: 21406147

Group type: EXPERIMENTAL
Intervention: Injection using the VibraJect
Number of subjects: 90

Group type: COMPARATOR
Intervention: Injection as usual (control)
Number of subjects: 90
Study: 19921358

Group type: EXPERIMENTAL
Intervention: Intrathecal injection of 0.5% isobaric bupivacaine, 2.8 ml plus morphine, 0.05 mg (Group B)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Intrathecal injection of 0.5% isobaric bupivacaine, 2.8 ml (Group A)
Number of subjects: 20
Study: 16513860

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 335

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 335
Study: 15041008

Group type: EXPERIMENTAL
Intervention: Topical anaesthesia with Xylocain solution
Number of subjects: 20

Group type: COMPARATOR
Intervention: Physiological Sodium solution (Control)
Number of subjects: 20
Study: 11230036

Group type: EXPERIMENTAL
Intervention: Baseline predictors of frequent contact
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Continued frequent contact after 2 years
Number of subjects: 0
Study: 9066031

Group type: EXPERIMENTAL
Intervention: Liquid combination of DTP-PRP-T vaccine
Number of subjects: 262

Group type: COMPARATOR
Intervention: Lyophilized PRP-T reconstituted with DTP
Number of subjects: 262
Study: 8446136

Group type: EXPERIMENTAL
Intervention: Follow-up colonoscopy at one and three years
Number of subjects: 1418

Group type: COMPARATOR
Intervention: Follow-up colonoscopy at three years only
Number of subjects: 1418
Study: 3530137

Group type: COMPARATOR
Intervention: MF (Mitomycin and 5-Fluorouracil)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: MF.BH-AC (Mitomycin, 5-Fluorouracil, and BH-AC)
Number of subjects: 64
Study: 29678360

Group type: EXPERIMENTAL
Intervention: HerSwab™ self-sampling
Number of subjects: 1217

Group type: EXPERIMENTAL
Intervention: Cobas® swab self-sampling
Number of subjects: 1217

Group type: COMPARATOR
Intervention: Physician-collected sample
Number of subjects: 1217

Group type: COMPARATOR
Intervention: Cytology on physician-collected specimen
Number of subjects: 1217
Study: 26892135

Group type: EXPERIMENTAL
Intervention: Icosabutate 600 mg once daily
Number of subjects: 87

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87